Author

Priyanka Verma

University of MichiganORCID 0000-0002-3035-4964Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

John VargaiD· 2 shared Adam KlumppiD· 1 shared Bharath YalavarthiiD· 1 shared Carlos E. CórdovaiD· 1 shared Catherine Vasquez-Hernandez· 1 shared Dibyendu BhattacharyyaiD· 1 shared Francesco Del GaldoiD· 1 shared Jenna Silverman· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

John VargaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Imbalance of Ciliary Programs Drives Fibroblast Differentiation and Fibrotic Signaling in Systemic Sclerosis

Le My Tu Nguyen, Carlos E. Córdova, Paulene Sapao, Catherine Vasquez-Hernandez, Adam Klumpp, Le Phuc Diem Nguyen, Poulami Dey, Johann Eli Gudjonsson, Rebecca L. Ross, Francesco Del Galdo, Natalia A. Riobo‐Del Galdo, Priyanka Verma, John Varga, Maria Eugenia Teves

This study identifies ciliary program imbalance as a driver of fibroblast-to-myofibroblast reprogramming in systemic sclerosis, suggesting ciliotherapy as a potential treatment.

bioRxiv · Feb 25, 2026 · PreprintCell Biology

Targeting activated IL-23 signaling in Scleroderma by tildrakizumab

Priyanka Verma, Roberta M Goncalves, Swarna Bale, Jenna Silverman, Timothy Hamill, Kris Shah, Bharath Yalavarthi, Dibyendu Bhattacharyya, Swati Bhattacharyya, John Varga

This study investigates the role of IL-23 in systemic sclerosis (SSc) and shows that tildrakizumab reduces fibrosis in experimental models.

bioRxiv · Feb 2, 2026 · PreprintImmunology